SCTR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Purmorphamine (SCHEMBL1548273)	1.00	9/20
Purmorphamine (SCHEMBL29358352)	1.00	9/20
SCHEMBL14075696	0.98	9/20
SCHEMBL14075697	0.95	9/20
SCHEMBL16367807	0.89	9/20
SCHEMBL14075700	0.76	9/20
SCHEMBL14707305	0.76	9/20
SCHEMBL14075692	0.74	9/20
SCHEMBL14075698	0.72	9/20
SCHEMBL14075689	0.71	9/20
SCHEMBL14088204	0.71	9/20
SCHEMBL14075684	0.71	9/20
SCHEMBL15102965	0.70	9/20
SCHEMBL28900682	0.67	9/20
SCHEMBL14075703	0.67	9/20
SCHEMBL14075707	0.67	9/20
SCHEMBL14075699	0.65	9/20
SCHEMBL14075715	0.60	9/20
SCHEMBL23961998	0.58	9/20
SCHEMBL14075691	0.74	8/20

Clinical trials — most relevant to SCTR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion	PHASE3	COMPLETED
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome	PHASE3	COMPLETED
Liraglutide in Adolescents With Type 1 Diabetes	PHASE3	COMPLETED
Secretin in Ex-situ Liver Perfusion	PHASE1/PHASE2	ENROLLING_BY_INVITATION
Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer	PHASE2	COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy	PHASE1/PHASE2	RECRUITING
Metabolic Effects of Non-Nutritive Sweeteners	PHASE1/PHASE2	COMPLETED
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide	PHASE1/PHASE2	RECRUITING
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia	PHASE2	COMPLETED
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.	PHASE1	RECRUITING
The Role of Endocannabinoids in Insulin Production and Action	PHASE1	COMPLETED
Effect of Repeated Doses of YF476 on Stomach Acidity	PHASE1	COMPLETED
Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms	EARLY_PHASE1	COMPLETED
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients	EARLY_PHASE1	UNKNOWN
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention	nan	NOT_YET_RECRUITING
The Role of Secretin on the Energy Homeostasis	nan	COMPLETED
Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus	nan	NOT_YET_RECRUITING
Selective Activation of the Adrenomedullin Receptors in Migraine	nan	NOT_YET_RECRUITING
The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes	nan	COMPLETED
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	nan	RECRUITING
Observational Study on GEP-and Pulm-NET Treated at FPG	nan	RECRUITING
Sucralose and Lactisole Additions to OGTT in Humans	nan	COMPLETED
Effect of GLP-1 on Postprandial Lipid Metabolism	nan	UNKNOWN
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy	nan	COMPLETED
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.	nan	COMPLETED
Dietary Carbohydrate and GERD in Veterans	nan	COMPLETED
The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SCTR binder may also engage these)

Protein	Name	Similarity
O46502	—	1.000	O46502 →
P30083	—	1.000	P30083 →
Q28992	—	1.000	Q28992 →
P97751	—	0.999	P97751 →
P23811	—	0.999	P23811 →
VIPR2	Vasoactive intestinal polypeptide receptor 2	0.998	landscape →
VIPR1	Vasoactive intestinal polypeptide receptor 1	0.997	landscape →
O35659	—	0.997	O35659 →
Q5FWI2	—	0.997	Q5FWI2 →
P41588	—	0.995	P41588 →
GLP1R	Glucagon-like peptide 1 receptor	0.993	landscape →
GCGR	Glucagon receptor	0.993	landscape →
P35000	—	0.993	P35000 →
Q0P543	—	0.992	Q0P543 →
Q61606	—	0.992	Q61606 →
P32301	—	0.991	P32301 →
P34999	—	0.991	P34999 →
P43219	—	0.990	P43219 →
GIPR	Gastric inhibitory polypeptide receptor	0.989	landscape →
GHRHR	Growth hormone-releasing hormone receptor	0.988	landscape →
P43218	—	0.988	P43218 →
A0A2Z2U4G9	—	0.987	A0A2Z2U4G9 →
P32082	—	0.986	P32082 →
Q29627	—	0.985	Q29627 →
P30082	—	0.985	P30082 →
Q91085	—	0.985	Q91085 →
P70205	—	0.985	P70205 →
Q02644	—	0.985	Q02644 →
CALCR	Calcitonin receptor	0.985	landscape →
Q9IB86	—	0.984	Q9IB86 →